Multifocal Lens Centration and Its Effect on Visual Performance in a Presbyopic Population
BUICK
1 other identifier
interventional
35
1 country
1
Brief Summary
The purpose of this study is to use a corneal topographer, a device that is readily available in most optometric practices, in order to determine the position of the multifocal (MF) contact lens (CL) optics in relation to the optics of the eye. The specific purpose of this study is to evaluate if there is a relationship between the positioning of the optics of the study lenses and the objective and subjective visual performance as well as participant satisfaction. The MF CL lenses will be fitted to two groups of participants (previously unsuccessful vs. currently successful MF CL wearers). HYPOTHESES
- The measurement of the power distribution acquired from the Medmont E300 corneal topographer is effective in determining MF CL lens centration and is a predictor of MF CL success.
- There is a difference in MF CL centration, determined by corneal topography, between successful and unsuccessful MF CL wearers.
- MF CL centration, determined by corneal topography, is correlated with visual performance, determined by ocular aberrometry, measures of visual acuity and subjective satisfaction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2014
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
August 26, 2014
CompletedFirst Posted
Study publicly available on registry
August 28, 2014
CompletedStudy Start
First participant enrolled
December 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2015
CompletedMay 29, 2015
May 1, 2015
4 months
August 26, 2014
May 28, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
Decentration
Decentration (in mm and axis of decentration) of the multifocal contact lens optical center relative to ocular reference points (e.g. the pupil center or the line of sight), determined using difference maps produced by the Medmont E300 corneal topographer.
Day 1
Secondary Outcomes (8)
Visual Acuity (high contrast) at distance
Day 1
Visual Acuity (high contrast) at intermediate distance
Day 1
Visual Acuity (high contrast) at near
Day 1
Visual Acuity (low contrast) at distance
Day 1
Visual Acuity (low contrast) at intermediate distance
Day 1
- +3 more secondary outcomes
Study Arms (3)
Acuvue Oasys for Presbyopia
EXPERIMENTALAcuvue Oasys for Presbyopia contact lenses worn
PureVision2 for Presbyopia
EXPERIMENTALPureVision2 for Presbyopia contact lenses worn
Biofinity Multifocal
EXPERIMENTALBiofinity Multifocal contact lenses worn
Interventions
Acuvue Oasys for Presbyopia contact lenses worn
PureVision2 for Presbyopia contact lenses worn
Eligibility Criteria
You may qualify if:
- Is at least 42 years of age and has full legal capacity to volunteer;
- Has read and signed an information consent letter;
- Is willing and able to follow instructions and maintain the appointment schedule;
- Has previous experience with wearing MF CLs;
- Is able to be successfully fitted with all study lenses;
- Has a vertex-corrected spherical distance prescription of +6.00 to 8.00D (inclusive) in both eyes;
- Has a spectacle cylinder ≤0.75D in both eyes;
- Requires a reading addition of ≥+1.00D;
You may not qualify if:
- A person will be excluded from the study if he/she:
- Is participating in any concurrent clinical or research study;
- Has any known active\* ocular disease and/or infection;
- Has a systemic condition that in the opinion of the investigator may affect a study outcome variable;
- Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable;
- Has a known sensitivity to the diagnostic pharmaceuticals to be used in the study;
- Is pregnant, lactating or planning a pregnancy at the time of enrolment;
- Is aphakic;
- Has undergone refractive error surgery;
- Has monocular best-corrected VA of worse than 20/30 in each eye;
- Has amblyopia or strabismus;
- Has anisometropia \>2D between both eyes
- For the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. Mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. Neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Waterloolead
- Johnson & Johnson Vision Carecollaborator
Study Sites (1)
Centre for Contact Lens Research, University of Waterloo
Waterloo, Ontario, N2L 3G1, Canada
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lyndon Jones, PhD
CCLR, University of Waterloo
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 26, 2014
First Posted
August 28, 2014
Study Start
December 1, 2014
Primary Completion
April 1, 2015
Study Completion
April 1, 2015
Last Updated
May 29, 2015
Record last verified: 2015-05